Literature DB >> 21900220

Modern approaches to localized cancer of the esophagus.

Robert E Glasgow1, David H Ilson, James A Hayman, Hans Gerdes, Mary F Mulcahy, Jaffer A Ajani.   

Abstract

The clinical spectrum of esophageal cancer has changed dramatically over the past couple of decades. Most notably, a profound rise in esophageal adenocarcinoma and decrease in the incidence of squamous carcinomas have occurred. An understanding of the factors that influence survival for patients with localized esophageal cancer has evolved concomitantly with these changes in epidemiology. Significant advancement in endoscopic and radiographic staging allows for more selective use of treatment modalities. The treatment of localized esophageal cancer mandates a multidisciplinary approach, with treatment tailored to disease extent, location, histology, and an accurate assessment of pretreatment staging. Despite these improvements in the staging and use of multimodality therapy, only modest improvements in patient survival have been observed. This article summarizes these modern approaches to localized cancer of the esophagus.

Entities:  

Mesh:

Year:  2011        PMID: 21900220     DOI: 10.6004/jnccn.2011.0074

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  3 in total

Review 1.  Endoscopic options for early stage esophageal cancer.

Authors:  Pari M Shah; Hans Gerdes
Journal:  J Gastrointest Oncol       Date:  2015-02

2.  Improving Adherence to Cancer Treatment by Addressing Quality of Life in Patients With Advanced Gastrointestinal Cancers.

Authors:  Andrea L Cheville; Steven R Alberts; Teresa A Rummans; Jeffrey R Basford; Maria I Lapid; Jeff A Sloan; Daniel V Satele; Matthew M Clark
Journal:  J Pain Symptom Manage       Date:  2015-05-12       Impact factor: 3.612

3.  Current treatment options for the management of esophageal cancer.

Authors:  Mark R Mawhinney; Robert E Glasgow
Journal:  Cancer Manag Res       Date:  2012-11-02       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.